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doi:10.1016/j.jtcvs.2003.10.051Objectives: We determined the long-term patency rates of coronary artery grafts
with endoscopically harvested saphenous veins.
Methods: Patency rates were established in 51 patients with 130 distal saphenous
vein grafts using contrast-enhanced electron beam computed tomography at 3.74 
0.65 years after coronary artery bypass grafting. A similar group of 50 patients with
131 distal grafts were studied prospectively using the same methodology at 0.7 
0.19 years after coronary artery bypass grafting.
Results: The overall patency rates were 95.4% in the retrospective group and 95.3%
in the prospective group. Sequential grafts tended to have a patency advantage over
independent grafts.
Conclusions: These data compare favorably with reported patency rates for tradi-
tionally harvested saphenous veins. Endoscopic saphenous vein harvesting, in
addition to previous favorable reports on pain, complications, and costs, is now
shown to provide comparable or better patency rates in comparison with tradition-
ally harvested veins.
Despite the advent, success,1-6 and increasing acceptance of endo-scopic vein harvesting (EVH) for coronary artery bypass grafting(CABG), a single major concern is unresolved. The relativelongevity of the endoscopically harvested saphenous vein remainsunknown.
We6 and others1-5 have shown that EVH for the short term is safe and effective,
with less leg pain and morbidity than traditionally harvested saphenous veins.
Although there is concern that the vein may be subject to more intense manipulation
during endoscopic harvest, which may lead to restenosis or occlusion, early histo-
logic and physiologic studies2,5,7-9 do not support this. Further, indirect clinical
studies10 show there is no increase in adverse events (death, myocardial infarction,
or angina) at the 18-month follow-up.
We followed an early cadre of patients6 undergoing EVH for CABG to determine
long-term graft patency by contrast-enhanced electron beam computed tomography
(EBCT). In addition, we followed a matched group of more recent patients pro-
spectively to examine the occurrence of early graft stenosis or occlusion. Because
coronary angiography carries a procedural risk (especially in asymptomatic patients)
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able method to directly measure graft patency.
Methods
Patients who had undergone or were scheduled for CABG with
endoscopically harvested saphenous veins were recruited for
study. Patients undergoing a reoperation (2 CABGs) were ex-
cluded. Cardiopulmonary bypass with cold cardioplegic solution
was used in all cases. All anastomoses were constructed with
distracted running sutures. This study was reviewed and approved
by the institutional review board of Edward Hospital. All patients
consented to join the study. Two groups of patients were studied.
Group 1 was a retrospective group of 51 patients. These patients
were a subset of those patients who comprised a study detailing the
methods and outcomes of EVH.6 EVH was accomplished in the
retrospective group with a single 2- to 3-cm incision medially
above the knee. The greater saphenous vein was identified, and a
space was created for the insertion of a subcutaneous dissector. A
300-mm 30° endoscope was used for visualization, and a dissector
was used for blunt dissection (CardioVations, Ethicon, Somerville,
NJ). Endoscopic miniscissors were used for sharp dissection. Clips
were used for large side branches and to close the most distal
portion of the vein. Endoscopic sutures were used at the proximal
portion of the dissection before vein removal.
Group 2 was a demographically similar set of 50 patients
recruited prospectively. A similar technique was used, with addi-
tion of the use of an intraoperative Medi-Stim Butterfly
(Medtronic, Minneapolis, Minn) device for flow and pulsatility
index measurements.
Patients in Group 1 (retrospective) were selected for study by
sequentially telephoning (maximum of 3 calls) each patient who
met selection criteria until the requisite number of 50 was reached.
A total of 133 patients were contacted. Patients in Group 2 (pro-
spective) were asked to enroll in the study in a consecutive manner
when they underwent their initial surgical consult for CABG. A
total of 86 patients were asked to participate to reach the number
of 50 participants.
The majority (82%, n  214) of grafts examined in this study
were sequential grafts. There were 47 (18%) individual grafts.
Although most of these patients had an arterial graft placed at
surgery, only saphenous vein grafts (SVGs) were examined in this
study.
EBCT Scans
To determine patency, the relatively new technology of contrast-
enhanced EBCT scans was used. An Insight workstation (Neo
Imagery Technologies, City of Industry, Calif) was used for read-
ing the scans.
All scans were performed on an Imatron C150 Electron Beam
CT scanner (General Electric-Imatron, South San Francisco,
Calif). An antecubital intravenous catheter was inserted, and 18G
to 20G hypodermic needles were used. All patients had electro-
cardiogram monitoring throughout the procedure. Image acquisi-
tion was gated to 60% of the respiratory rate interval. After scout
imaging was obtained to determine the area of interest for scan-
ning, circulatory time was determined using a timing run. Iohexol
(20 mL) was injected over a period of 5 to 7 seconds, and scanning
at timed intervals was performed over the ascending aorta. Image
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maximum contrast density in Hounsfield units within the ascend-
ing aorta. Images were obtained in 3  2-mm slice thicknesses
from the base of the heart superiorly through the ascending aorta.
Patients with heart rates less than 60/min were treated with
atropine to achieve rates greater than 60/min to avoid prolonged
breath holding during scanning. All patients were given supple-
mental oxygen and instructed in breath-holding techniques. Imme-
diately before image acquisition, all patients received a 0.4 mg
dose of sublingual nitroglycerin spray to maximize coronary va-
sodilatation.
Iohexol doses of 3 to 5 mL/s were then administered for
contrast opacification of the venous conduits. Combined with the
timing run, 150 mL of contrast dye was used for the typical study.
Images were then transferred to a Neo Imager Technology Insight
workstation for data storage and analysis. Two-dimensional axial
imagery, 3-dimensional reconstruction with volume rendering,
maximum intensity projection, and 3-dimensional reconstructions
were all used to interpret the images. Both Groups 1 (retrospective)
and 2 (prospective) were interpreted independently by 2 experi-
enced CT angiography readers (S.C. and M.B.) who were unaware
of the other’s readings.
Graft patency was categorically scored as (1) patent without
evidence of disease; (2) patent, but with evidence of atheroscle-
rotic disease defined as more than 50% occlusion; and (3) totally
(100%) occluded.
Statistics
This study was designed to provide an accurate description of the
occlusion rate of the SVGs with time. Previous work6 with the
retrospective patient group had shown a clinically apparent occlu-
sion rate of 2.6% at 1 year. With this rate and an estimated
standard error of the population of 13.65%, a sample size of 50
would give 95% confidence intervals such that we could accurately
predict the true occlusion rate between 0% and 9% using 1-tailed
tests. The Clopper-Pearson statistic11 was chosen to determine the
confidence intervals. These data could then be compared among
the 2 groups and historic controls.
Both univariate and multivariate logistic regression were used
to determine the relative contribution of several variables to the
outcome of total occlusion. In these analyses, if there were 1 or
more total occlusions for any given patient, the dependent variable
“occlusion” was listed as positive. Open but diseased vessels were
tabulated as open for these analyses.
Data are presented as means  SDs for quantitative measures.
Numbers and percentages are used for qualitative measures. Chi-
square tests were used for incidence rate testing, and statistical
analysis was aided by Systat 7.0 (SPSS, Chicago, Ill). Analysis of
variance with Bonferroni tests was used for quantitative variables
when contrasting the 2 subject groups to the previous patient




Groups 1 and 2 were similar in demographics (Table 1).
Group 1 also closely reflected the demographics from the
original group of patients from whom it was derived except
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ETfor the proportion of current smokers, which was signifi-
cantly greater at the original presentation. Although there
seemed to be a higher percentage of male patients in Group
1 versus either of the other groups, this did not prove
statistically significant overall (P  .103) or compared with
Group 2 alone (P  .062).
Overall Graft Patency Readings
All grafts were categorically evaluated as open, diseased, or
totally occluded by each of the 2 readers, independently.
The operative reports indicated that 261 vein grafts were
placed overall (Groups 1 and 2, sequential plus individual
grafts). Both readers read all 261 grafts. The agreement
between the 2 readers was 91.6% (239/261 grafts). Consen-
sus readings were used for 19 of the remaining 22 grafts.
Three grafts remained with different readings by the 2
readers.
Patency Rates by Group
In Group 1 (retrospective), the EBCT scan was performed in
patients 3.74  0.65 years (range 3.37-4.31 years) after the
initial CABG. Of the 131 grafts in this group, 122 were
open, 2 were diseased, 6 were occluded, and 1 was read
either as open (S.C.) or diseased (M.B.). This latter graft is
excluded from the following calculations. The open graft
rate was 95.4% (124 open grafts; the diseased grafts were
included in the open tally for analysis). The occluded graft
rate was 4.6% (Clopper-Pearson 95% confidence interval
1.97%-8.90%). These data and the breakdown by sequential
and independent grafts can be found in Table 2.
In Group 2 (prospective), the EBCT scan was performed
in patients 0.70  0.19 years (range 0.47-1.11 years) after
the initial CABG. Of the 130 grafts in this group, 120 were
open, 2 were diseased, 6 were occluded, and 2 were read as
occluded/diseased and open/occluded by the 2 readers.
These latter 2 grafts are excluded from the following cal-
culations. Again placing the diseased grafts into the open
tally, there was a 95.3% patency rate (122 open grafts) and
TABLE 1. Demographic variables
Group 1
Age (y) 65.9 9.7 (range 45.8–82.5)
Gender 90.2% males
Height (in) 69.7 4.5
Weight (lb) 192.1 34.1




Diabetes (% with) 31.4%
Hypertension (% with) 62.8%
*†Indicates a difference between marked values at the indicated P value4.7% occlusion rate (Clopper-Pearson 95% confidence in-
The Journal of Thoraciterval 2.00%-8.84%). These data and the breakdown by
sequential and independent grafts are shown in Table 3.
Patency Rates by Type of Graft
Although this study was not designed and powered to test
the difference between sequential versus independent grafts,
there seemed to be a higher overall rate of occlusion for the
independent grafts versus the sequential grafts. The patency
rates of sequential grafts versus independent grafts in Group
1 (retrospective) are given in Table 2. Without the input
from the diseased grafts, the totally occluded rate was
3.57% (4/112) for the sequential grafts in Group 1. The
respective rate for the independent grafts was 11.1% (2/18).
This difference was not significant (P  .466). The same
analysis for Group 2 (prospective) (Table 3) showed occlu-
sion rates of 2% (2/100) for the sequential grafts and 14.3%
(4/28) for the independent grafts. This difference was sta-
tistically significant (P  .043). Combining the groups
showed occlusion rates of 2.8% for the sequential grafts and
13% for the independent grafts, a significant difference (P
 .017).
Influence of Predictive Variables on Patency
Factors including hypertension, number of distal grafts,
total cholesterol, high-density lipoprotein, low-density li-
Group 2
Comparative data
(Reference 6) P value
63.2 9.3 (46.7–82.7) 61.8 10.2 (in 1997) P  .2
74% males 79.1% males P  .103
68.1 4.5 68.9 4.0 P  .2
193.3 41.1 189.4 38.5 P  .2
2.6 0.7 2.5 1.0 P  .2
92%† 52.7%*† P  .001
36% 23.6% P  .20
66% 62.7% P  .20
TABLE 2. Group 1 (retrospective) saphenous vein graft
status
Number of
grafts Open Open but diseased Occluded
Sequential
grafts
112* 107 1 4
Independent
grafts
18 15 1 2
Total grafts 130 122 2 6
*One sequential graft was not resolvable by consensus; S.C. read it as
open, and M.B. read it as diseased..poprotein, triglycerides, diabetes, smoking status, need for
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nary angioplasty, presence of coronary symptoms, beta
blockers, angiotensin-converting enzyme inhibitors, aspirin,
statins, calcium blockers, coumadin, age, and weight were
examined for possible contribution to occlusion. This was
accomplished with both univariate and multivariate logistic
regression. None of these variables, taken singly, were
significant for predicting occlusion. Using the 3 most likely
variables from the univariate analyses, namely, diabetes (P
 .3), need for a stress test (P  .3), and angiotensin-
converting enzyme inhibitors (P  .4), in a multivariate
logistic regression resulted in no significant predictive value
for any of the variables.
Discussion
Although endoscopically harvested veins for CABG gener-
ally ensure favorable patient-related outcomes,1-6 they have
not been subject to the long-term follow-up of traditionally
harvested saphenous veins. There is a concern that greater
damage might be done to a vein with endoscopic harvesting
than there is with traditional open harvesting.2,5,7,8 There
have been several studies that have examined this question.
Meyer and colleagues,8 in a small study, showed no histo-
logic differences in intima, media, or adventitia of endo-
scopically versus traditionally harvested veins. Further-
more, von Willebrand factor protein and CD34 were not
different between the 2 methods. Griffith and colleagues7
showed similar endothelial, elastic lamina, and smooth mus-
cle continuity as well as medial and adventitial connective
tissue uniformity between traditional versus endoscopically
harvested veins. Using a small subset of veins taken from a
large group of patients, Crouch and colleagues5 reported no
decrement in vein integrity regardless of harvest technique.
Kiaii and colleagues2 also reported minimal and nonsignif-
icant changes in vein histology independent of harvest tech-
nique. These data indicate that endoscopically harvested
veins should perform as well as traditionally harvested
TABLE 3. Group 2 (prospective) saphenous vein graft sta-
tus
Number of
grafts Open Open but diseased Occluded
Sequential
grafts
100* 97 1 2
Independent
grafts
28† 23 1 4
Total grafts 128 129 2 6
*One sequential graft was not resolvable by consensus; S.C. read it as
occluded, and M.B. read it as diseased.
†One independent graft was not resolvable by consensus; S.C. read it as
open, and M.B. read it as occluded.veins.
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grafts was first described in 1983.12 EBCT seems well
suited for imaging of the coronary artery. It has a unique
combination of high temporal (100 ms/slice) and spatial
(0.35  0.35  2.5 mm) resolutions, allowing visualization
of small lesions. Furthermore, ECG triggering allows image
acquisition during the slow portion of coronary motion
(diastole).13,14 Contrast-enhanced EBCT (or contrast-en-
hanced electron beam angiography [EBA]) is an emerging
technology with the potential for obtaining essentially non-
invasive coronary arteriograms (Figures 1 and 2). The use of
EBA to detect the patency of CABG was reported as early
as 1986.15 Baumgartner and colleagues16 used EBCT in
symptomatic patients in the early postoperative period and
found 5 of 51 (9.8%) independent SVGs occluded. Dai and
colleagues17 used EBCT to evaluate coronary grafts at 15
months (range 7 days-120 months) after CABG. Of 296
SVGs placed in 150 patients, 228 (77%) were patent. Of
note in their study is the comparison of 7 patients with 12
grafts in whom EBCT showed 7 patent and 5 occluded
grafts, findings that were confirmed by conventional an-
giography. Lu and colleagues18 compared EBCT with con-
ventional angiography in 26 patients with 91 grafts. They
found a sensitivity of 87.5% (14/16 stenosed grafts correctly
Figure 1. Contrast-enhanced EBCT of a 71-year-old patient 3
years after CABG, with patent graft to obtuse marginal (arrow),
followed by 30% stenosis in graft before insertion into the pos-
terior descending artery.identified) and a 90.7% specificity (68/75 patent grafts).
ch 2004
Davis et al Evolving Technology
ETSVGs, which are generally of large caliber and have little
cardiac motion, are especially well suited for noninvasive
imaging with EBA. Flow studies (sequential image acqui-
sition to determine the rate of contrast enhancement at a
particular point in the anatomy) demonstrate graft patency
with sensitivities of 93% to 96% and specificities of 86% to
100%.19-21 Using 3-dimensional visualization in patients
post-CABG demonstrated a sensitivity of 92% to 100% and
a specificity of 91% to 100% for establishing the patency of
SVGs compared with conventional coronary angiogra-
phy.18,22,23 A recent study by Achenbach and colleagues22
demonstrated a sensitivity of 97% and specificity of 100%
for obstructions of SVG using EBA, compared with inva-
sive cardiac catheterization.
From these studies it is apparent that with greater than
90% accuracy, contrast EBCT can be used for noninvasive
tracking of patients who underwent CABG with saphenous
vein or arterial grafts.
The long-term patency rates of venous grafts used for
CABG are a known factor when using traditionally har-
vested saphenous veins. These rates must be used compar-
atively to ensure that endoscopic harvest carries no added
risk. Early trials showed 69% patency at 1 year,24 77%
patency between 9 and 18 months,25 and 82% patency at 18
months and 5 years.26 Despite significant technical ad-
vances since these early studies, graft failure remains high at
15% to 30% at 1 year and progressing to 50% by 10
years.27,28 Manninen and colleagues28 found 87% of SVGs
open at 2 years (range 13-31 months). This value included
4 diseased but patent grafts. Fitzgibbon and colleagues29
reported patency rates of 81% and 75% at 1 and 5 years,
respectively, in a large series of patients.
More recently, Souza and colleagues,30 using a vein
harvest technique that includes taking a surrounding pedicle
of tissue with the saphenous vein, reported an occlusion rate
of 4.8% (6/124 grafts, 95.2% patency) at 18 months (range
9-24 months). This article provides a benchmark of early
graft patency. Calculations using the data of their article
show that the Clopper-Pearson 95% confidence intervals are
2.1% for the lower limit and 9.4% for the upper limit.
Our data are almost identical to Souza and colleagues’
data30 for both prospective and retrospective groups. Even if
there is a small underestimation of occlusion rates because
of the EBCT testing, our data clearly demonstrate that EVH
does not contribute to a higher incidence of graft failure.
Indeed, our patency rates compare quite favorably with
those commonly accepted and are likely better than those
reported by Dai and colleagues,17 who reported patency
rates of 77% for coronary grafts using EBCT over a very
wide range of times.
Of interest are the nearly identical findings for the 3.7-
year grafts versus the recent grafts. This indicates that early
graft failure likely accounts for nearly all of the total occlu-
The Journal of Thoracisions that occur. Longer term follow-up seems essential to
determine whether there is a progression of occlusions in
endoscopically harvested saphenous veins as there is for
conventionally harvested veins.
These low rates of vein graft occlusion answer one of the
final challenges to the widespread application of EVH. With
the excellent patient satisfaction, good short-term outcomes
in terms of infections, pain, and costs, and the low occlusion
rates we report, EVH should be the standard for saphenous
vein harvest.
We thank R. Patel, PhD, for his review of the statistical
analyses used in this article.
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